Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
| Autor: | Naveen Pemmaraju, Keyur P. Patel, Elias Jabbour, Jeffery Jorgensen, Renee Ward, Michael Andreeff, Jing Ning, Naval Daver, Marina Konopleva, Hagop M. Kantarjian, Tapan M. Kadia, Jorge E. Cortes, Farhad Ravandi, Adam R. Craig, Sherry Pierce, Guillermo Garcia-Manero, Graciela M. Nogueras González, Kenneth Vaughan, Courtney D. DiNardo, Mark Brandt, Gautam Borthakur |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Acute Myeloid Leukemia medicine.medical_specialty Myeloid Neoplasm Residual Decitabine Vosaroxin Gastroenterology Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Mucositis Medicine Humans Naphthyridines Survival analysis Aged business.industry Incidence (epidemiology) Remission Induction Age Factors Myeloid leukemia Hematology Middle Aged medicine.disease Survival Analysis Surgery Leukemia Leukemia Myeloid Acute Thiazoles medicine.anatomical_structure Treatment Outcome chemistry 030220 oncology & carcinogenesis Myelodysplastic Syndromes Mutation Azacitidine Female business Biomarkers 030215 immunology medicine.drug |
| Zdroj: | Haematologica |
| ISSN: | 1592-8721 |
| Popis: | Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in patients ≥60 years of age with newly diagnosed acute myeloid leukemia (n=58) or myelodysplastic syndrome (≥10% blasts) (n=7) in a phase II non-randomized trial. The initial 22 patients received vosaroxin 90 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to seven cycles. Due to a high incidence of mucositis the subsequent 43 patients were given vosaroxin 70 mg/m2 on days 1 and 4. These 65 patients, with a median age of 69 years (range, 60-78), some of whom with secondary leukemia (22%), adverse karyotype (35%), or TP53 mutation (20%), are evaluable. The overall response rate was 74% including complete remission in 31 (48%), complete remission with incomplete platelet recovery in 11 (17%), and complete remission with incomplete count recovery in six (9%). The median number of cycles to response was one (range, 1-4). Grade 3/4 mucositis was noted in 17% of all patients. The 70 mg/m2 induction dose of vosaroxin was associated with similar rates of overall response (74% versus 73%) and complete remission (51% versus 41%, P=0.44), reduced incidence of mucositis (30% versus 59%, P=0.02), reduced 8-week mortality (9% versus 23%; P=0.14), and improved median overall survival (14.6 months versus 5.5 months, P=0.007). Minimal residual disease-negative status by multiparametric flow-cytometry at response (± 3 months) was achieved in 21 of 39 (54%) evaluable responders and was associated with better median overall survival (34.0 months versus 8.3 months, P=0.023). In conclusion, the combination of vosaroxin with decitabine is effective and well tolerated at a dose of 70 mg/m2 and warrants randomized prospective evaluation. ClinicalTrials.gov: NCT01893320. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|